Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury

Description

The objective is to determine the effectiveness of pulsatile flow during cardiopulmonary bypass to reduce the incidence of acute kidney injury after cardiac surgery. Investigators will also evaluate the safety and impact of pulsatile flow on clinical outcomes compared to non-pulsatile flow during cardiopulmonary bypass.

Conditions

Acute Kidney Injury, Hemolysis, Thrombocytopenia, Surgery

Study Overview

Study Details

Study overview

The objective is to determine the effectiveness of pulsatile flow during cardiopulmonary bypass to reduce the incidence of acute kidney injury after cardiac surgery. Investigators will also evaluate the safety and impact of pulsatile flow on clinical outcomes compared to non-pulsatile flow during cardiopulmonary bypass.

Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury: Randomized Controlled Trial

Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury

Condition
Acute Kidney Injury
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado Hospital, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Able to provide informed consent
  • * Scheduled for elective cardiac surgery with cardiopulmonary bypass
  • * Emergency procedures
  • * Scheduled for heart or lung transplantation
  • * Scheduled for ventricular assist device implantation
  • * Use of the Medtronic Elongated Once-Piece Arterial Cannula
  • * Diagnosed with sepsis
  • * Diagnosed with delirium
  • * Experiencing hemodynamic instability (heart rate \> 100 and systolic blood pressure \< 90)
  • * Requiring mechanical circulatory support
  • * Requiring vasoactive medications

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Nathan J Clendenen, MD, MS, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2028-10